Shrinking Spleens and Nodes, Expanding Horizons: Leniolisib and the Future of Activated Phosphoinositide 3-Kinase Delta Syndrome
The Journal of Allergy and Clinical Immunology: In Practice · 2026-07 · 14 (7) · 1525-1528
DOI: 10.1016/j.jaip.2026.03.040 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026-07. Verfasst von Kittipos Visitsunthorn und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Lymphoproliferative Disorders, Phosphoinositide-3 Kinase Inhibitors, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Activated phosphoinositide 3-kinase delta syndrome is an inborn error of immunity characterized by combination of immunodeficiency with immune dysregulation and classified within autoimmune lymphoproliferative immunodeficiencies. Early therapeutic strategies extrapolated from autoimmune lymphoproliferative syndrome, including mTOR inhibition with sirolimus, provided variable control of lymphoproliferation. Recognition of constitutive PI3Kδ signaling led to the development of leniolisib, approved by the U.S. Food and Drug Administration in 2023, marking a transition toward pathway-specific precision therapy. In this Clinical Perspective, we review the evolution of targeted therapy in APDS, the biochemical structure and selectivity of leniolisib relative to other PI3K inhibitors, and the mechanistic distinction between proximal PI3Kδ inhibition and downstream mTOR blockade. We summarize current clinical evidence and practical considerations for dosing and monitoring in the absence of serum drug-level assays. Finally, we outline key unresolved questions, including long-term disease modification, biomarker validation, pediatric outcomes, treatment sequencing and combination strategies, while positioning leniolisib relative to hematopoietic stem cell transplantation, and desirability of it’s wider global access.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. Electronic address: korao@nih.gov.
Förderung
- Intramural NIH HHS
- National Institutes of Health
Zitieren
APA
Visitsunthorn, K., & Rao, V. K. (2026). Shrinking Spleens and Nodes, Expanding Horizons: Leniolisib and the Future of Activated Phosphoinositide 3-Kinase Delta Syndrome. The Journal of Allergy and Clinical Immunology: In Practice, 14(7), 1525-1528. https://doi.org/10.1016/j.jaip.2026.03.040
Vancouver
Visitsunthorn K, Rao VK. Shrinking Spleens and Nodes, Expanding Horizons: Leniolisib and the Future of Activated Phosphoinositide 3-Kinase Delta Syndrome. The Journal of Allergy and Clinical Immunology: In Practice. 2026;14(7):1525-1528. doi:10.1016/j.jaip.2026.03.040
BibTeX
@article{Visitsunthorn2026,
author = {Visitsunthorn, Kittipos and Rao, V Koneti},
title = {Shrinking Spleens and Nodes, Expanding Horizons: Leniolisib and the Future of Activated Phosphoinositide 3-Kinase Delta Syndrome},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2026},
volume = {14},
number = {7},
pages = {1525--1528},
doi = {10.1016/j.jaip.2026.03.040}
}
EUVIMED